|
KMID : 1007020090070030187
|
|
Korean Soceity of Osteroporosis
2009 Volume.7 No. 3 p.187 ~ p.197
|
|
|
A Comparison of the Effects of Raloxifene and Hormon Therapy on Lipid Profile and Bone Mineral Density in Postmenopausal Osteopenia Women
|
|
Kim Jun-Seok
Jung Min-Hyung
Kim Ji-Yeol
Lee Tae-Hwa
Lee Ji-Young
Yang Seoung-Oh
Jung Hyuk
Kim Heung-Yeol
|
|
|
Abstract
|
|
|
Objectives: To compare the raloxifene lipid profile and bone mineral density to estrogen therapy in postmenopausal women with osteopenia.
Methods: In this prospective clinical trial, a total of 132 natural or surgical menopausal women at the Department of Obstetrics and Gynecology of Kosin University Hospital between June 2007 and December 2008 were studied. The effects of raloxifene (Evistaⓡ 60mg/day, N=42) and estrogen therapy (Premarinⓡ 0.625mg/day, N=84) were compared in terms of the lipid profile (total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride) changes in bone mineral density over 24 months. The lipid profile and bone mineral density measurements were performed at baseline, and at 12 and 24months.
Results: Women treated with raloxifene for 24 months had a decrease in the total cholesterol and triglyceride levels by 4.8% and 5.5%, and increase in the LDL-C and HDL-C levels by 1.7% and 7.1%, respectively these differences were not statistically significant. Women treated with estrogen for 24 months had a decrease in the total cholesterol level by 1.1%, an increase in the triglyceride level, LDL-C and HDL-C levels by 2.5%, 6.1%, and 5.3%, respectively these differences were not statistically significant. Women treated with estrogen for 24 months had a decrease in the bone mineral density of the lumbar spine by 2.7% and increase in the bone mineral density of the femur neck by 0.7%, respectively these differences were not statistically significant. There was no statistically significant difference in total cholesterol, LDL-C and HDL-C, triglyceride, and bone mineral density between the raloxifene and estrogen therapy groups.
Conclusion: There was no statistically significant difference in the effects of raloxifene and estrogen on the lipid profile and bone mineral density in postmenopausal women after 24 months. Further studies are necessary to establish a definitive comparison of the effects of raloxifene and estrogen therapy on the lipid profile and bone mineral density of postmenopausal women.
|
|
|
KEYWORD
|
|
|
Menopause, Raloxifene, Estrogen, Lipid profile, Bone mineral density
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|